Sensitivity/Specificity — MCQs

Q: You are tasked with analyzing the negative predictive value of an experimental serum marker for ovarian cancer. You choose to enroll 2,000 patients across multiple clinical sites, including both 1,000 patients with ovarian cancer and 1,000 age-matched controls. From the disease and control subgroups, 700 and 100 are found positive for this novel serum marker, respectively. Which of the following represents the NPV for this test?

900 / (900 + 300). ***900 / (900 + 300)*** - The **Negative Predictive Value (NPV)** is the probability that a person with a **negative test result** does not have the disease. It is calculated as **true negatives (TN)** divided by the sum of true negatives and **false negatives (FN)**, i.e., TN / (TN + FN). - In this scenario: there are 1,000 ovarian cancer patients, and 700 tested positive, meaning **300 tested negative (false negatives)**. There are 1,000 controls, and 100 tested positive, meaning **900 tested negative (true negatives)**. Therefore, NPV = 900 / (900 + 300). *700 / (700 + 300)* - This calculation represents the sensitivity of the test, which is the proportion of true positives among all individuals with the disease (700 true positives / 1000 diseased individuals). - It does not account for the true negatives or false positives, which are crucial for determining predictive values. *700 / (300 + 900)* - This formula mixes elements and does not correspond to a standard measure of test validity. - The numerator (700) is the number of true positives, and the denominator incorrectly combines false negatives (300) and true negatives (900). *700 / (700 + 100)* - This calculation represents the **Positive Predictive Value (PPV)**, which is the probability that a person with a **positive test result** actually has the disease (700 true positives / (700 true positives + 100 false positives)). - It does not assess the negative predictive power of the test. *900 / (900 + 100)* - This calculation represents the **specificity** of the test, which is the proportion of true negatives among all individuals without the disease (900 true negatives / 1000 controls). - While this involves true negatives, it does not account for false negatives, which are essential for calculating NPV.

Q: Specificity for breast examination is traditionally rather high among community practitioners. A team of new researchers sets forth a goal to increase specificity in detection of breast cancer from the previously reported national average of 74%. Based on the following results, has the team achieved its goal? Breast cancer screening results: Patients WITH breast cancer | Patients WITHOUT breast cancer Test is Positive (+) 21 | 5 Test is Negative (-) 7 | 23

Yes, the team has achieved an increase in specificity of approximately 8%.. ***Yes, the team has achieved an increase in specificity of approximately 8%.*** - Specificity is calculated as **True Negatives / (True Negatives + False Positives)**. In this case, specificity = 23 / (23 + 5) = 23 / 28 = 0.8214 or **82.14%**. - Comparing this to the national average of 74%, the increase is 82.14% - 74% = **8.14%**. *No, the research team’s results lead to nearly the same specificity as the previous national average.* - The calculated specificity is **82.14%**, which is significantly higher than the 74% national average, not nearly the same. - An **8% increase** represents a substantial improvement in the ability of the test to correctly identify individuals without the disease. *Yes, the team has achieved an increase in specificity of over 15%.* - The calculated increase in specificity is **8.14%**, which is less than 15%. - This option incorrectly overestimates the magnitude of the improvement. *It can not be determined, as the prevalence of breast cancer is not listed.* - Prevalence is used to calculate **positive and negative predictive values**, but not sensitivity or specificity. - Specificity can be directly calculated from the provided data on true negatives and false positives. *It can not be determined, since the numbers affiliated with the first trial are unknown.* - To answer the question, we only need the **original national average specificity (74%)** for comparison and the current trial's results to calculate the new specificity. - The raw numbers from the "first trial" (national average) are not required to determine if the goal was met.

Q: An inpatient psychiatrist recently had two patients who developed serious gastrointestinal infections while taking clozapine. He was concerned that his patients had developed agranulocytosis, a relatively rare but dangerous adverse event associated with clozapine. When the psychiatrist checked the absolute neutrophil count (ANC) of both patients, one was 450/mm3, while the other was 700/mm3 (N=1,500/mm3). According to the clozapine REMS (Risk Evaluation and Mitigation Strategy) program, severe neutropenia in clozapine recipients has often been defined as an absolute neutrophil count (ANC) less than 500/mm3. Changing the cutoff value to 750/mm3 would affect the test performance of ANC with regard to agranulocytosis in which of the following ways?

Increased false positives. ***Increased false positives*** - Raising the **ANC cutoff** from 500/mm³ to 750/mm³ means more individuals with an ANC between 500 and 750/mm³ will now be classified as having neutropenia. - This increases the likelihood of classifying patients without agranulocytosis as having the condition, thereby increasing **false positives**. *Decreased true positives* - A higher cutoff would likely lead to an **increase in true positives**, not a decrease, as more cases meeting the criteria for severe neutropenia would be identified. - It would capture more patients who genuinely have low ANC, even if they don't develop full-blown agranulocytosis. *Increased positive predictive value* - An increase in **false positives** would lead to a decrease in **positive predictive value (PPV)**, as a smaller proportion of positive test results would truly represent agranulocytosis. - PPV is the probability that a positive test result reflects the actual presence of the disease. *Unchanged specificity* - **Specificity** is the ability of the test to correctly identify those *without* the disease. By lowering the threshold (making it easier to test positive), specificity would decrease, not remain unchanged. - Many healthy individuals with ANC between 500-750/mm³ would now be incorrectly classified as having severe neutropenia. *Decreased sensitivity* - **Sensitivity** refers to the ability of a test to correctly identify those *with* the disease. By lowering the cutoff (making it easier to test positive for neutropenia), sensitivity would increase, not decrease. - More true cases of severe neutropenia (and potential agranulocytosis) would be detected earlier.

Q: A home drug screening test kit is currently being developed. The cut-off level is initially set at 4 mg/uL, which is associated with a sensitivity of 92% and a specificity of 97%. How might the sensitivity and specificity of the test change if the cut-off level is changed to 2 mg/uL?

Sensitivity = 97%, specificity = 96%. ***Sensitivity = 97%, specificity = 96%*** - Lowering the cut-off from 4 mg/uL to 2 mg/uL means that more individuals will be classified as **positive** (anyone with drug levels ≥2 mg/uL instead of ≥4 mg/uL). This change will **increase the sensitivity** (capturing more true positives, fewer false negatives) but **decrease the specificity** (more false positives among those without the condition). - Therefore, sensitivity will increase (e.g., to 97%), and specificity will decrease (e.g., to 96%), reflecting the fundamental trade-off between these metrics. *Sensitivity = 92%, specificity = 97%* - This option reflects the **original values** at the 4 mg/uL cut-off and does not account for the change in the threshold. - A change in the cut-off level will inherently alter the test's performance characteristics. *Sensitivity = 95%, specificity = 98%* - This option suggests an increase in **both sensitivity and specificity**, which is generally not possible by simply changing the cut-off level in the same direction. - There is typically an **inverse relationship** between sensitivity and specificity when adjusting the cut-off threshold. *Sensitivity = 100%, specificity = 97%* - Reaching **100% sensitivity** while maintaining a high specificity is highly unlikely with a simple cut-off adjustment. - While sensitivity would increase with a lower cut-off, achieving perfect sensitivity is unrealistic in clinical practice. *Sensitivity = 90%, specificity = 99%* - This option suggests a **decrease in sensitivity** and an **increase in specificity**. - A lower cut-off would lead to more positive results, thus increasing sensitivity and reducing specificity, which contradicts the proposed values.

Q: A scientist in Chicago is studying a new blood test to detect Ab to EBV with increased sensitivity and specificity. So far, her best attempt at creating such an exam reached 82% sensitivity and 88% specificity. She is hoping to increase these numbers by at least 2 percent for each value. After several years of work, she believes that she has actually managed to reach a sensitivity and specificity much greater than what she had originally hoped for. She travels to China to begin testing her newest blood test. She finds 2,000 patients who are willing to participate in her study. Of the 2,000 patients, 1,200 of them are known to be infected with EBV. The scientist tests these 1,200 patients' blood and finds that only 120 of them tested negative with her new exam. Of the patients who are known to be EBV-free, only 20 of them tested positive. Given these results, which of the following correlates with the exam's specificity?

98%. ***98%*** - **Specificity** measures the proportion of **true negatives** among all actual negatives. - In this case, 800 patients are known to be EBV-free (actual negatives), and 20 of them tested positive (false positives). This means 800 - 20 = 780 tested negative (true negatives). Specificity = (780 / 800) * 100% = **98%**. *82%* - This value represents the *original sensitivity* before the scientist’s new attempts to improve the test. - It does not reflect the *newly calculated specificity* based on the provided data. *90%* - This value represents the *newly calculated sensitivity* of the test, not the specificity. - Out of 1200 EBV-infected patients, 120 tested negative (false negatives), meaning 1080 tested positive (true positives). Sensitivity = (1080 / 1200) * 100% = 90%. *84%* - This percentage is not directly derived from the information given for either sensitivity or specificity after the new test results. - It does not correspond to any of the calculated values for the new test's performance. *86%* - This percentage is not directly derived from the information given for either sensitivity or specificity after the new test results. - It does not correspond to any of the calculated values for the new test's performance.

Q: The World Health Organization suggests the use of a new rapid diagnostic test for the diagnosis of malaria in resource-limited settings. The new test has a sensitivity of 70% and a specificity of 90% compared to the gold standard test (blood smear). The validity of the new test is evaluated at a satellite health center by testing 200 patients with a positive blood smear and 150 patients with a negative blood smear. How many of the tested individuals are expected to have a false negative result?

60. ***Correct Option: 60*** - **False negatives** occur in individuals who have the disease but test negative. This is directly related to the test's **sensitivity**. - Given a sensitivity of 70%, 30% of actual positive cases (100% - 70%) will be missed. With 200 patients having a positive blood smear (meaning they have malaria), 30% of 200 is 0.30 × 200 = **60**. *Incorrect Option: 15* - This number represents the expected number of **false positives** (150 patients without disease × 10% false positive rate = 15). - However, the question asks for **false negatives**, not false positives. *Incorrect Option: 135* - This value represents the number of **true negatives** (150 patients without malaria × 90% specificity = 135). - It does not represent false negative results. *Incorrect Option: 155* - This appears to be a distractor number that doesn't correspond to any standard diagnostic test calculation in this scenario. - It does not represent false negatives or any meaningful combination of the given parameters. *Incorrect Option: 195* - This number might be derived from incorrectly applying formulas or miscalculating the relationship between sensitivity and false negatives. - It does not represent the correct calculation for false negatives.

You are tasked with analyzing the negative predictive value of an experimental serum marker for ovarian cancer. You choose to enroll 2,000 patients across multiple clinical sites, including both 1,000 patients with ovarian cancer and 1,000 age-matched controls. From the disease and control subgroups, 700 and 100 are found positive for this novel serum marker, respectively. Which of the following represents the NPV for this test?

Specificity for breast examination is traditionally rather high among community practitioners. A team of new researchers sets forth a goal to increase specificity in detection of breast cancer from the previously reported national average of 74%. Based on the following results, has the team achieved its goal? Breast cancer screening results: Patients WITH breast cancer | Patients WITHOUT breast cancer Test is Positive (+) 21 | 5 Test is Negative (-) 7 | 23

An inpatient psychiatrist recently had two patients who developed serious gastrointestinal infections while taking clozapine. He was concerned that his patients had developed agranulocytosis, a relatively rare but dangerous adverse event associated with clozapine. When the psychiatrist checked the absolute neutrophil count (ANC) of both patients, one was 450/mm3, while the other was 700/mm3 (N=1,500/mm3). According to the clozapine REMS (Risk Evaluation and Mitigation Strategy) program, severe neutropenia in clozapine recipients has often been defined as an absolute neutrophil count (ANC) less than 500/mm3. Changing the cutoff value to 750/mm3 would affect the test performance of ANC with regard to agranulocytosis in which of the following ways?

A home drug screening test kit is currently being developed. The cut-off level is initially set at 4 mg/uL, which is associated with a sensitivity of 92% and a specificity of 97%. How might the sensitivity and specificity of the test change if the cut-off level is changed to 2 mg/uL?

A group of investigators who are studying individuals infected with Trypanosoma cruzi is evaluating the ELISA absorbance cutoff value of serum samples for diagnosis of infection. The previous cutoff point is found to be too high, and the researchers decide to lower the threshold by 15%. Which of the following outcomes is most likely to result from this decision?

A physician at an internal medicine ward notices that several of his patients have hyponatremia without any associated symptoms. Severe hyponatremia, often defined as < 120 mEq/L, is associated with altered mental status, coma, and seizures, and warrants treatment with hypertonic saline. Because some patients are chronically hyponatremic, with serum levels < 120 mEq/L, but remain asymptomatic, the physician is considering decreasing the cutoff for severe hyponatremia to < 115 mEq/L. Changing the cutoff to < 115 mEq/L would affect the validity of serum sodium in predicting severe hyponatremia requiring hypertonic saline in which of the following ways?

A scientist in Chicago is studying a new blood test to detect Ab to EBV with increased sensitivity and specificity. So far, her best attempt at creating such an exam reached 82% sensitivity and 88% specificity. She is hoping to increase these numbers by at least 2 percent for each value. After several years of work, she believes that she has actually managed to reach a sensitivity and specificity much greater than what she had originally hoped for. She travels to China to begin testing her newest blood test. She finds 2,000 patients who are willing to participate in her study. Of the 2,000 patients, 1,200 of them are known to be infected with EBV. The scientist tests these 1,200 patients' blood and finds that only 120 of them tested negative with her new exam. Of the patients who are known to be EBV-free, only 20 of them tested positive. Given these results, which of the following correlates with the exam's specificity?

A student health coordinator plans on leading a campus-wide HIV screening program that will be free for the entire undergraduate student body. The goal is to capture as many correct HIV diagnoses as possible with the fewest false positives. The coordinator consults with the hospital to see which tests are available to use for this program. Test A has a sensitivity of 0.92 and a specificity of 0.99. Test B has a sensitivity of 0.95 and a specificity of 0.96. Test C has a sensitivity of 0.98 and a specificity of 0.93. Which of the following testing schemes should the coordinator pursue?

The World Health Organization suggests the use of a new rapid diagnostic test for the diagnosis of malaria in resource-limited settings. The new test has a sensitivity of 70% and a specificity of 90% compared to the gold standard test (blood smear). The validity of the new test is evaluated at a satellite health center by testing 200 patients with a positive blood smear and 150 patients with a negative blood smear. How many of the tested individuals are expected to have a false negative result?

Q10

A public health campaign increases vaccination rates against human papillomaviruses 16 and 18. Increased vaccination rates would have which of the following effects on the Papanicolaou test?

Sensitivity/Specificity US Medical PG Practice Questions and MCQs

Question 1: You are tasked with analyzing the negative predictive value of an experimental serum marker for ovarian cancer. You choose to enroll 2,000 patients across multiple clinical sites, including both 1,000 patients with ovarian cancer and 1,000 age-matched controls. From the disease and control subgroups, 700 and 100 are found positive for this novel serum marker, respectively. Which of the following represents the NPV for this test?

A. 700 / (700 + 300)
B. 700 / (300 + 900)
C. 700 / (700 + 100)
D. 900 / (900 + 100)
E. 900 / (900 + 300) (Correct Answer)

Explanation: ***900 / (900 + 300)*** - The **Negative Predictive Value (NPV)** is the probability that a person with a **negative test result** does not have the disease. It is calculated as **true negatives (TN)** divided by the sum of true negatives and **false negatives (FN)**, i.e., TN / (TN + FN). - In this scenario: there are 1,000 ovarian cancer patients, and 700 tested positive, meaning **300 tested negative (false negatives)**. There are 1,000 controls, and 100 tested positive, meaning **900 tested negative (true negatives)**. Therefore, NPV = 900 / (900 + 300). *700 / (700 + 300)* - This calculation represents the sensitivity of the test, which is the proportion of true positives among all individuals with the disease (700 true positives / 1000 diseased individuals). - It does not account for the true negatives or false positives, which are crucial for determining predictive values. *700 / (300 + 900)* - This formula mixes elements and does not correspond to a standard measure of test validity. - The numerator (700) is the number of true positives, and the denominator incorrectly combines false negatives (300) and true negatives (900). *700 / (700 + 100)* - This calculation represents the **Positive Predictive Value (PPV)**, which is the probability that a person with a **positive test result** actually has the disease (700 true positives / (700 true positives + 100 false positives)). - It does not assess the negative predictive power of the test. *900 / (900 + 100)* - This calculation represents the **specificity** of the test, which is the proportion of true negatives among all individuals without the disease (900 true negatives / 1000 controls). - While this involves true negatives, it does not account for false negatives, which are essential for calculating NPV.

Question 2: Specificity for breast examination is traditionally rather high among community practitioners. A team of new researchers sets forth a goal to increase specificity in detection of breast cancer from the previously reported national average of 74%. Based on the following results, has the team achieved its goal? Breast cancer screening results: Patients WITH breast cancer | Patients WITHOUT breast cancer Test is Positive (+) 21 | 5 Test is Negative (-) 7 | 23

A. No, the research team’s results lead to nearly the same specificity as the previous national average.
B. Yes, the team has achieved an increase in specificity of over 15%.
C. It can not be determined, as the prevalence of breast cancer is not listed.
D. It can not be determined, since the numbers affiliated with the first trial are unknown.
E. Yes, the team has achieved an increase in specificity of approximately 8%. (Correct Answer)

Explanation: ***Yes, the team has achieved an increase in specificity of approximately 8%.*** - Specificity is calculated as **True Negatives / (True Negatives + False Positives)**. In this case, specificity = 23 / (23 + 5) = 23 / 28 = 0.8214 or **82.14%**. - Comparing this to the national average of 74%, the increase is 82.14% - 74% = **8.14%**. *No, the research team’s results lead to nearly the same specificity as the previous national average.* - The calculated specificity is **82.14%**, which is significantly higher than the 74% national average, not nearly the same. - An **8% increase** represents a substantial improvement in the ability of the test to correctly identify individuals without the disease. *Yes, the team has achieved an increase in specificity of over 15%.* - The calculated increase in specificity is **8.14%**, which is less than 15%. - This option incorrectly overestimates the magnitude of the improvement. *It can not be determined, as the prevalence of breast cancer is not listed.* - Prevalence is used to calculate **positive and negative predictive values**, but not sensitivity or specificity. - Specificity can be directly calculated from the provided data on true negatives and false positives. *It can not be determined, since the numbers affiliated with the first trial are unknown.* - To answer the question, we only need the **original national average specificity (74%)** for comparison and the current trial's results to calculate the new specificity. - The raw numbers from the "first trial" (national average) are not required to determine if the goal was met.

Question 3: An inpatient psychiatrist recently had two patients who developed serious gastrointestinal infections while taking clozapine. He was concerned that his patients had developed agranulocytosis, a relatively rare but dangerous adverse event associated with clozapine. When the psychiatrist checked the absolute neutrophil count (ANC) of both patients, one was 450/mm3, while the other was 700/mm3 (N=1,500/mm3). According to the clozapine REMS (Risk Evaluation and Mitigation Strategy) program, severe neutropenia in clozapine recipients has often been defined as an absolute neutrophil count (ANC) less than 500/mm3. Changing the cutoff value to 750/mm3 would affect the test performance of ANC with regard to agranulocytosis in which of the following ways?

A. Decreased true positives
B. Increased positive predictive value
C. Increased false positives (Correct Answer)
D. Unchanged specificity
E. Decreased sensitivity

Explanation: ***Increased false positives*** - Raising the **ANC cutoff** from 500/mm³ to 750/mm³ means more individuals with an ANC between 500 and 750/mm³ will now be classified as having neutropenia. - This increases the likelihood of classifying patients without agranulocytosis as having the condition, thereby increasing **false positives**. *Decreased true positives* - A higher cutoff would likely lead to an **increase in true positives**, not a decrease, as more cases meeting the criteria for severe neutropenia would be identified. - It would capture more patients who genuinely have low ANC, even if they don't develop full-blown agranulocytosis. *Increased positive predictive value* - An increase in **false positives** would lead to a decrease in **positive predictive value (PPV)**, as a smaller proportion of positive test results would truly represent agranulocytosis. - PPV is the probability that a positive test result reflects the actual presence of the disease. *Unchanged specificity* - **Specificity** is the ability of the test to correctly identify those *without* the disease. By lowering the threshold (making it easier to test positive), specificity would decrease, not remain unchanged. - Many healthy individuals with ANC between 500-750/mm³ would now be incorrectly classified as having severe neutropenia. *Decreased sensitivity* - **Sensitivity** refers to the ability of a test to correctly identify those *with* the disease. By lowering the cutoff (making it easier to test positive for neutropenia), sensitivity would increase, not decrease. - More true cases of severe neutropenia (and potential agranulocytosis) would be detected earlier.

Question 4: A home drug screening test kit is currently being developed. The cut-off level is initially set at 4 mg/uL, which is associated with a sensitivity of 92% and a specificity of 97%. How might the sensitivity and specificity of the test change if the cut-off level is changed to 2 mg/uL?

A. Sensitivity = 92%, specificity = 97%
B. Sensitivity = 95%, specificity = 98%
C. Sensitivity = 100%, specificity = 97%
D. Sensitivity = 90%, specificity = 99%
E. Sensitivity = 97%, specificity = 96% (Correct Answer)

Explanation: ***Sensitivity = 97%, specificity = 96%*** - Lowering the cut-off from 4 mg/uL to 2 mg/uL means that more individuals will be classified as **positive** (anyone with drug levels ≥2 mg/uL instead of ≥4 mg/uL). This change will **increase the sensitivity** (capturing more true positives, fewer false negatives) but **decrease the specificity** (more false positives among those without the condition). - Therefore, sensitivity will increase (e.g., to 97%), and specificity will decrease (e.g., to 96%), reflecting the fundamental trade-off between these metrics. *Sensitivity = 92%, specificity = 97%* - This option reflects the **original values** at the 4 mg/uL cut-off and does not account for the change in the threshold. - A change in the cut-off level will inherently alter the test's performance characteristics. *Sensitivity = 95%, specificity = 98%* - This option suggests an increase in **both sensitivity and specificity**, which is generally not possible by simply changing the cut-off level in the same direction. - There is typically an **inverse relationship** between sensitivity and specificity when adjusting the cut-off threshold. *Sensitivity = 100%, specificity = 97%* - Reaching **100% sensitivity** while maintaining a high specificity is highly unlikely with a simple cut-off adjustment. - While sensitivity would increase with a lower cut-off, achieving perfect sensitivity is unrealistic in clinical practice. *Sensitivity = 90%, specificity = 99%* - This option suggests a **decrease in sensitivity** and an **increase in specificity**. - A lower cut-off would lead to more positive results, thus increasing sensitivity and reducing specificity, which contradicts the proposed values.

Question 5: A group of investigators who are studying individuals infected with Trypanosoma cruzi is evaluating the ELISA absorbance cutoff value of serum samples for diagnosis of infection. The previous cutoff point is found to be too high, and the researchers decide to lower the threshold by 15%. Which of the following outcomes is most likely to result from this decision?

A. Increased negative predictive value (Correct Answer)
B. Unchanged true positive results
C. Decreased sensitivity
D. Increased specificity
E. Increased positive predictive value

Explanation: ***Increased negative predictive value*** - Lowering the absorbance cutoff for the ELISA test makes it **easier to test positive**, which increases **sensitivity** (more true positives are detected, fewer false negatives occur). - **Negative predictive value (NPV)** is the probability that a person who tests negative truly does not have the disease: NPV = TN / (TN + FN). - When the cutoff is lowered, **fewer infected individuals will be missed** (false negatives decrease). This reduction in false negatives improves the NPV because there are fewer disease-positive individuals in the "test-negative" group. - Therefore, a negative test result becomes **more reliable at ruling out infection**, increasing the NPV. *Unchanged true positive results* - Lowering the cutoff means that samples with lower absorbance values (previously below threshold) from truly infected individuals will now be classified as positive. - This directly **increases the number of true positive results**, not keeps them unchanged. - The whole purpose of lowering the threshold is to capture more infected cases. *Decreased sensitivity* - **Sensitivity** = TP / (TP + FN), the ability to correctly identify those with disease. - Lowering the cutoff **increases sensitivity** by making it easier to test positive, thereby capturing more true positives and reducing false negatives. - A lower threshold would never decrease sensitivity—it does the opposite. *Increased specificity* - **Specificity** = TN / (TN + FP), the ability to correctly identify those without disease. - Lowering the cutoff causes some uninfected individuals to now test positive (false positives increase). - This **decreases specificity**, not increases it, as fewer true negatives remain. *Increased positive predictive value* - **PPV** = TP / (TP + FP), the probability that a positive test indicates true disease. - While lowering the cutoff increases true positives, it also **increases false positives more substantially**. - The increased false positives dilute the proportion of true positives among all positive results, thereby **decreasing the PPV**.

Question 6: A physician at an internal medicine ward notices that several of his patients have hyponatremia without any associated symptoms. Severe hyponatremia, often defined as < 120 mEq/L, is associated with altered mental status, coma, and seizures, and warrants treatment with hypertonic saline. Because some patients are chronically hyponatremic, with serum levels < 120 mEq/L, but remain asymptomatic, the physician is considering decreasing the cutoff for severe hyponatremia to < 115 mEq/L. Changing the cutoff to < 115 mEq/L would affect the validity of serum sodium in predicting severe hyponatremia requiring hypertonic saline in which of the following ways?

A. Increased sensitivity and decreased positive predictive value
B. Increased specificity and decreased positive predictive value
C. Decreased specificity and increased negative predictive value
D. Increased specificity and decreased negative predictive value (Correct Answer)
E. Decreased sensitivity and decreased positive predictive value

Explanation: ***Increased specificity and decreased negative predictive value*** - **Increasing the cutoff from <120 to <115 mEq/L makes the diagnostic criteria MORE STRINGENT** (fewer patients classified as "severe"). - **Specificity INCREASES**: With a stricter cutoff, fewer patients without true severe disease (asymptomatic chronic hyponatremia) will be falsely labeled as "severe" and unnecessarily treated with hypertonic saline. Specificity measures the ability to correctly identify patients who do NOT have the target condition (symptomatic severe hyponatremia requiring treatment). - **Negative Predictive Value (NPV) DECREASES**: Patients with sodium levels between 115-120 mEq/L will now test "negative" for severe hyponatremia (falling above the new threshold), but some of these patients may still develop symptoms requiring treatment. Therefore, a "negative" test result (Na >115) becomes less reliable at ruling out the need for future treatment, decreasing NPV. - **Note**: Sensitivity will DECREASE (more symptomatic patients with Na 115-120 will be missed), and PPV will INCREASE (those identified as severe are more likely to truly need treatment). *Increased sensitivity and decreased positive predictive value* - Moving the cutoff to a more stringent value (<115 mEq/L) would **decrease sensitivity**, not increase it, because patients with sodium 115-120 mEq/L who have symptoms would be missed. - The positive predictive value would **increase**, not decrease, because patients classified as "severe" under the stricter criteria are more likely to truly require hypertonic saline. *Increased specificity and decreased positive predictive value* - **Increased specificity** is correct, as explained above. - However, **PPV would increase**, not decrease, with a more stringent cutoff. When fewer patients are classified as "severe," those who meet the stricter criteria are more likely to truly have severe disease requiring treatment. *Decreased specificity and increased negative predictive value* - Specificity would **increase**, not decrease, with stricter diagnostic criteria (fewer false positives). - NPV would **decrease**, not increase, because patients just above the new threshold (Na 115-120) who test "negative" may still require treatment. *Decreased sensitivity and decreased positive predictive value* - **Decreased sensitivity** is correct—the stricter cutoff will miss symptomatic patients with sodium 115-120 mEq/L. - However, **PPV would increase**, not decrease. With stricter criteria, patients identified as "severe" are more likely to truly have severe disease requiring hypertonic saline.

Question 7: A scientist in Chicago is studying a new blood test to detect Ab to EBV with increased sensitivity and specificity. So far, her best attempt at creating such an exam reached 82% sensitivity and 88% specificity. She is hoping to increase these numbers by at least 2 percent for each value. After several years of work, she believes that she has actually managed to reach a sensitivity and specificity much greater than what she had originally hoped for. She travels to China to begin testing her newest blood test. She finds 2,000 patients who are willing to participate in her study. Of the 2,000 patients, 1,200 of them are known to be infected with EBV. The scientist tests these 1,200 patients' blood and finds that only 120 of them tested negative with her new exam. Of the patients who are known to be EBV-free, only 20 of them tested positive. Given these results, which of the following correlates with the exam's specificity?

A. 82%
B. 90%
C. 84%
D. 86%
E. 98% (Correct Answer)

Explanation: ***98%*** - **Specificity** measures the proportion of **true negatives** among all actual negatives. - In this case, 800 patients are known to be EBV-free (actual negatives), and 20 of them tested positive (false positives). This means 800 - 20 = 780 tested negative (true negatives). Specificity = (780 / 800) * 100% = **98%**. *82%* - This value represents the *original sensitivity* before the scientist’s new attempts to improve the test. - It does not reflect the *newly calculated specificity* based on the provided data. *90%* - This value represents the *newly calculated sensitivity* of the test, not the specificity. - Out of 1200 EBV-infected patients, 120 tested negative (false negatives), meaning 1080 tested positive (true positives). Sensitivity = (1080 / 1200) * 100% = 90%. *84%* - This percentage is not directly derived from the information given for either sensitivity or specificity after the new test results. - It does not correspond to any of the calculated values for the new test's performance. *86%* - This percentage is not directly derived from the information given for either sensitivity or specificity after the new test results. - It does not correspond to any of the calculated values for the new test's performance.

Question 8: A student health coordinator plans on leading a campus-wide HIV screening program that will be free for the entire undergraduate student body. The goal is to capture as many correct HIV diagnoses as possible with the fewest false positives. The coordinator consults with the hospital to see which tests are available to use for this program. Test A has a sensitivity of 0.92 and a specificity of 0.99. Test B has a sensitivity of 0.95 and a specificity of 0.96. Test C has a sensitivity of 0.98 and a specificity of 0.93. Which of the following testing schemes should the coordinator pursue?

A. Test A on the entire student body followed by Test B on those who are positive
B. Test A on the entire student body followed by Test C on those who are positive
C. Test C on the entire student body followed by Test B on those who are positive
D. Test C on the entire student body followed by Test A on those who are positive (Correct Answer)
E. Test B on the entire student body followed by Test A on those who are positive

Explanation: ***Test C on the entire student body followed by Test A on those who are positive*** - To "capture as many correct HIV diagnoses as possible" (maximize true positives), the initial screening test should have the **highest sensitivity**. Test C has the highest sensitivity (0.98). - To "capture as few false positives as possible" (maximize true negatives and confirm diagnoses), the confirmatory test should have the **highest specificity**. Test A has the highest specificity (0.99). *Test A on the entire student body followed by Test B on those who are positive* - Starting with Test A (sensitivity 0.92) would miss more true positive cases than starting with Test C (sensitivity 0.98), failing the goal of **capturing as many cases as possible**. - Following with Test B (specificity 0.96) would result in more false positives than following with Test A (specificity 0.99). *Test A on the entire student body followed by Test C on those who are positive* - This scheme would miss many true positive cases initially due to Test A's lower sensitivity compared to Test C. - Following with Test C would introduce more false positives than necessary, as it has a lower specificity (0.93) than Test A (0.99). *Test C on the entire student body followed by Test B on those who are positive* - While Test C is a good initial screen for its high sensitivity, following it with Test B (specificity 0.96) is less optimal than Test A (specificity 0.99) for minimizing false positives in the confirmation step. - This combination would therefore yield more false positives in the confirmatory stage than using Test A. *Test B on the entire student body followed by Test A on those who are positive* - Test B has a sensitivity of 0.95, which is lower than Test C's sensitivity of 0.98, meaning it would miss more true positive cases at the initial screening stage. - While Test A provides excellent specificity for confirmation, the initial screening step is suboptimal for the goal of capturing as many diagnoses as possible.

Question 9: The World Health Organization suggests the use of a new rapid diagnostic test for the diagnosis of malaria in resource-limited settings. The new test has a sensitivity of 70% and a specificity of 90% compared to the gold standard test (blood smear). The validity of the new test is evaluated at a satellite health center by testing 200 patients with a positive blood smear and 150 patients with a negative blood smear. How many of the tested individuals are expected to have a false negative result?

A. 60 (Correct Answer)
B. 15
C. 135
D. 155
E. 195

Explanation: ***Correct Option: 60*** - **False negatives** occur in individuals who have the disease but test negative. This is directly related to the test's **sensitivity**. - Given a sensitivity of 70%, 30% of actual positive cases (100% - 70%) will be missed. With 200 patients having a positive blood smear (meaning they have malaria), 30% of 200 is 0.30 × 200 = **60**. *Incorrect Option: 15* - This number represents the expected number of **false positives** (150 patients without disease × 10% false positive rate = 15). - However, the question asks for **false negatives**, not false positives. *Incorrect Option: 135* - This value represents the number of **true negatives** (150 patients without malaria × 90% specificity = 135). - It does not represent false negative results. *Incorrect Option: 155* - This appears to be a distractor number that doesn't correspond to any standard diagnostic test calculation in this scenario. - It does not represent false negatives or any meaningful combination of the given parameters. *Incorrect Option: 195* - This number might be derived from incorrectly applying formulas or miscalculating the relationship between sensitivity and false negatives. - It does not represent the correct calculation for false negatives.

Question 10: A public health campaign increases vaccination rates against human papillomaviruses 16 and 18. Increased vaccination rates would have which of the following effects on the Papanicolaou test?

A. Decreased true positive rate
B. Decreased positive predictive value (Correct Answer)
C. Decreased negative predictive value
D. Increased positive likelihood ratio
E. Increased true negative rate

Explanation: ***Decreased positive predictive value*** - An increase in vaccination rates against **HPV 16 and 18** will reduce the **prevalence of cervical dysplasia and cancer** caused by these types. - With fewer true cases in the population, a Papanicolaou (Pap) test is more likely to yield a **false positive result** when it tests positive, thus decreasing its **positive predictive value**. - **PPV = TP/(TP+FP)** - when disease prevalence decreases, the number of true positives decreases while false positives remain relatively stable, reducing the overall PPV. *Decreased true positive rate* - The **true positive rate (sensitivity)** of the Pap test refers to its ability to correctly identify individuals with the disease (cervical dysplasia/cancer). - While the overall number of true positives will decrease due to reduced disease prevalence, the inherent ability of the test to detect existing disease (i.e., its sensitivity) is **not directly affected by vaccination rates**. - Sensitivity is an intrinsic test property: **Sensitivity = TP/(TP+FN)**. *Decreased negative predictive value* - The **negative predictive value** is the probability that a person with a negative test result truly does not have the disease. - As the prevalence of the disease decreases due to vaccination, the probability of a negative test being truly negative actually **increases**, leading to an **increased negative predictive value**. - **NPV = TN/(TN+FN)** - lower prevalence means fewer false negatives relative to true negatives. *Increased positive likelihood ratio* - The **positive likelihood ratio** describes how much more likely a positive test result is in someone with the disease compared to someone without the disease and is derived from sensitivity and specificity. - **LR+ = Sensitivity/(1-Specificity)** - vaccination reduces disease prevalence but does not inherently change the **diagnostic accuracy** (sensitivity and specificity) of the Pap test, so the likelihood ratio remains unchanged. *Increased true negative rate* - The **true negative rate (specificity)** of the Pap test refers to its ability to correctly identify individuals who do not have the disease. - While the overall number of true negatives will increase (because there are fewer cases to begin with), the inherent ability of the test to correctly identify healthy individuals (i.e., its specificity) is **not directly affected by the change in disease prevalence**. - Specificity is an intrinsic test property: **Specificity = TN/(TN+FP)**.

Question 11: A pharmaceutical corporation is developing a research study to evaluate a novel blood test to screen for breast cancer. They enrolled 800 patients in the study, half of which have breast cancer. The remaining enrolled patients are age-matched controls who do not have the disease. Of those in the diseased arm, 330 are found positive for the test. Of the patients in the control arm, only 30 are found positive. What is this test’s sensitivity?

A. 330 / (330 + 30)
B. 330 / (330 + 70) (Correct Answer)
C. 370 / (30 + 370)
D. 370 / (70 + 370)
E. 330 / (400 + 400)

Explanation: ***330 / (330 + 70)*** - **Sensitivity** measures the proportion of actual **positives** that are correctly identified as such. - In this study, there are **400 diseased patients** (half of 800). Of these, 330 tested positive (true positives), meaning 70 tested negative (false negatives). So sensitivity is **330 / (330 + 70)**. *330 / (330 + 30)* - This calculation represents the **positive predictive value**, which is the probability that subjects with a positive screening test truly have the disease. It uses **true positives / (true positives + false positives)**. - It does not correctly calculate **sensitivity**, which requires knowing the total number of diseased individuals. *370 / (30 + 370)* - This expression is attempting to calculate **specificity**, which is the proportion of actual negatives that are correctly identified. It would be **true negatives / (true negatives + false positives)**. - However, the numbers used are incorrect for specificity in this context given the data provided. *370 / (70 + 370)* - This formula is an incorrect combination of values and does not represent any standard epidemiological measure like **sensitivity** or **specificity**. - It is attempting to combine false negatives (70) and true negatives (370 from control arm) in a non-standard way. *330 / (400 + 400)* - This calculation attempts to divide true positives by the total study population (800 patients). - This metric represents the **prevalence of true positives within the entire study cohort**, not the test's **sensitivity**.

Question 12: A scientist in Boston is studying a new blood test to detect Ab to the parainfluenza virus with increased sensitivity and specificity. So far, her best attempt at creating such an exam reached 82% sensitivity and 88% specificity. She is hoping to increase these numbers by at least 2 percent for each value. After several years of work, she believes that she has actually managed to reach a sensitivity and specificity even greater than what she had originally hoped for. She travels to South America to begin testing her newest blood test. She finds 2,000 patients who are willing to participate in her study. Of the 2,000 patients, 1,200 of them are known to be infected with the parainfluenza virus. The scientist tests these 1,200 patients’ blood and finds that only 120 of them tested negative with her new test. Of the following options, which describes the sensitivity of the test?

A. 82%
B. 86%
C. 98%
D. 90% (Correct Answer)
E. 84%

Explanation: ***90%*** - **Sensitivity** is calculated as the number of **true positives** divided by the total number of individuals with the disease (true positives + false negatives). - In this scenario, there were 1200 infected patients (total diseased), and 120 of them tested negative (false negatives). Therefore, 1200 - 120 = 1080 patients tested positive (true positives). The sensitivity is 1080 / 1200 = 0.90, or **90%**. *82%* - This value was the **original sensitivity** of the test before the scientist improved it. - The question states that the scientist believes she has achieved a sensitivity "even greater than what she had originally hoped for." *86%* - This value is not directly derivable from the given data for the new test's sensitivity. - It might represent an intermediate calculation or an incorrect interpretation of the provided numbers. *98%* - This would imply only 24 false negatives out of 1200 true disease cases, which is not the case (120 false negatives). - A sensitivity of 98% would be significantly higher than the calculated 90% and the initial stated values. *84%* - This value is not derived from the presented data regarding the new test's performance. - It could be mistaken for an attempt to add 2% to the original 82% sensitivity, but the actual data from the new test should be used.

Question 13: A 26-year-old medical student comes to the physician with a 3-week history of night sweats and myalgias. During this time, he has also had a 3.6-kg (8-lb) weight loss. He returned from a 6-month tropical medicine rotation in Cambodia 1 month ago. A chest x-ray (CXR) shows reticulonodular opacities suggestive of active tuberculosis (TB). The student is curious about his likelihood of having active TB. He reads a study that compares sputum testing results between 2,800 patients with likely active TB on a basis of history, clinical symptoms, and CXR pattern and 2,400 controls. The results are shown: Sputum testing positive for TB Sputum testing negative for TB Total Active TB likely on basis of history, clinical symptoms, and CXR pattern 700 2100 2,800 Active TB not likely on basis of history, clinical symptoms, and CXR pattern 300 2100 2,400 Total 1000 4200 5,200 Which of the following values reflects the probability that a patient with a diagnosis of active TB on the basis of history, clinical symptoms, and CXR pattern actually has active TB?

A. 1.4
B. 0.50
C. 0.70
D. 0.88
E. 0.25 (Correct Answer)

Explanation: ***0.25*** - This value represents the **positive predictive value (PPV)** for active TB based on the initial clinical assessment criteria (history, symptoms, CXR). - PPV is calculated as the number of true positives (700) divided by the total number of individuals with a positive clinical diagnosis (700 + 2100 = 2800). So, 700 / 2800 = 0.25. - **This answers the question**: the probability that someone with a clinical diagnosis of active TB actually has the disease. *Incorrect 1.4* - This value is not a valid probability, as probabilities must be between 0 and 1.0. - It might arise from an incorrect calculation or misinterpretation of the provided data. *Incorrect 0.50* - This value does not correspond to any standard diagnostic metric calculated from the provided data. - The actual prevalence of TB (based on positive sputum) is 1000/5200 = 0.19, not 0.50. - This is likely a distractor with no meaningful interpretation in this context. *Incorrect 0.70* - This value represents the **sensitivity** of the sputum test for detecting active TB. - Sensitivity is calculated as true positives (700) divided by total with disease (700 + 300 = 1000). So, 700 / 1000 = 0.70. - Sensitivity tells us how good the test is at detecting disease when present, not the probability of having disease given a positive clinical diagnosis. *Incorrect 0.88* - This value represents the **specificity** of the clinical assessment. - Specificity is calculated as true negatives (2100) divided by total without disease (2100 + 300 = 2400). So, 2100 / 2400 = 0.875 ≈ 0.88. - Specificity tells us how good the assessment is at ruling out disease in those without it, not the probability of disease given a positive assessment.

Question 14: A 1-year-old boy is brought to the emergency room by his parents because of inconsolable crying and diarrhea for the past 6 hours. As the physician is concerned about acute appendicitis, she consults the literature base. She finds a paper with a table that summarizes data regarding the diagnostic accuracy of multiple clinical findings for appendicitis: Clinical finding Sensitivity Specificity Abdominal guarding (in children of all ages) 0.70 0.85 Anorexia (in children of all ages) 0.75 0.50 Abdominal rebound (in children ≥ 5 years of age) 0.85 0.65 Vomiting (in children of all ages) 0.40 0.63 Fever (in children from 1 month to 2 years of age) 0.80 0.80 Based on the table, the absence of which clinical finding would most accurately rule out appendicitis in this patient?

A. Guarding
B. Vomiting
C. Anorexia
D. Fever (Correct Answer)
E. Rebound

Explanation: ***Fever*** - To **rule out** a diagnosis, a finding with **high sensitivity** is desired. A high sensitivity means that if the disease is present, the test result will almost always be positive. Therefore, a negative test result (absence of the finding) in a highly sensitive test makes the presence of the disease unlikely. - Fever has a sensitivity of **0.80**, which means it is present in 80% of patients with appendicitis in the 1 month to 2 years age group. While 0.80 isn't extremely high, among the options applicable to this age group, it is the highest sensitivity for a "rule out" purpose. The absence of fever would therefore be the most useful finding to rule out appendicitis. *Guarding* - Guarding has a sensitivity of **0.70**, meaning it is present in 70% of appendicitis cases. While it's a useful sign, its sensitivity is lower than fever for ruling out the condition. - Its higher specificity (0.85) means that its presence makes appendicitis more likely, but its absence is less helpful for ruling it out compared to a highly sensitive finding. *Vomiting* - Vomiting has a sensitivity of **0.40**, which is very low. This means that 60% of patients with appendicitis do not experience vomiting. - Therefore, the absence of vomiting is not a reliable indicator to rule out appendicitis, as many appendicitis cases occur without it. *Anorexia* - Anorexia has a sensitivity of **0.75**. While higher than vomiting and guarding, it is still lower than fever (0.80) in the relevant age group for ruling out appendicitis. - Its low specificity (0.50) indicates it's a common symptom even in children without appendicitis, making its presence less diagnostic and its absence less useful for ruling out. *Rebound* - The table states that abdominal rebound data is for children **≥ 5 years of age**. The patient is 1 year old. - Therefore, this clinical finding's diagnostic accuracy is not applicable to the given patient's age and cannot be used for diagnosis or ruling out appendicitis.

Question 15: Health officials are considering making a change to the interpretation of the tuberculin skin test that will change the cut-off for a positive purified protein derivative (PPD) from 10 mm to 15 mm for healthcare workers. Which of the following can be expected as a result of this change?

A. Increase the sensitivity
B. Decrease the specificity
C. Decrease the sensitivity (Correct Answer)
D. No change to the sensitivity or specificity
E. Increase the precision

Explanation: ***Decrease the sensitivity*** - Increasing the PPD cut-off from 10 mm to 15 mm means fewer individuals will be identified as having a positive result. This will lead to more **false negatives**, thus **decreasing the sensitivity** of the test. - A higher threshold implies that only stronger reactions are considered positive, potentially missing milder but true cases of tuberculosis infection. *Increase the sensitivity* - Increasing the cut-off would result in fewer positive tests, not more, thereby **reducing the test's ability to correctly identify** those with the disease. - A higher threshold makes it harder to be classified as positive, which directly opposes an increase in sensitivity. *Decrease the specificity* - Increasing the cut-off criterion actually leads to an **increase in specificity**, as fewer healthy individuals would be misclassified as positive (**fewer false positives**). - A higher threshold ensures that only those with a very strong reaction are considered positive, reducing the chance of incorrectly identifying someone without the disease. *No change to the sensitivity or specificity* - Any alteration to the cut-off value in diagnostic testing directly impacts the trade-off between **sensitivity and specificity**. - Changing the diagnostic threshold inherently affects how well the test identifies true positives and true negatives. *Increase the precision* - **Precision** refers to the reproducibility of a measurement, meaning how close repeated measurements are to each other, not how many cases are correctly identified. - Changing the cut-off value does not alter the inherent precision of how the PPD induration is measured.

Question 16: A 17-year-old girl comes to the urgent care center after testing negative for HIV. She recently had sexual intercourse for the first time and had used a condom with her long-term boyfriend. She has no personal history of serious illness and no history of sexually transmitted infections. However, the patient is still worried about the possibility she has HIV despite the negative HIV test. She states that the package insert of the HIV test shows that of 100 patients who are found to be HIV-positive on PCR, 91 tested positive via the HIV test. Later in the day, a 23-year-old woman with a history of genitourinary chlamydia infection also comes to the urgent care center after testing negative for HIV. She states that she recently had unprotected intercourse with “someone who might have HIV.” If the test is conducted a second time on the 23-year-old patient, how will its performance compare to a second test conducted on the 17-year-old patient?

A. Decreased positive predictive value
B. Increased validity
C. Increased sensitivity
D. Decreased negative predictive value (Correct Answer)
E. Increased specificity

Explanation: ***Decreased negative predictive value*** - The 23-year-old patient has a higher **pre-test probability** of HIV due to unprotected intercourse with a high-risk partner and a history of STIs, which increases the likelihood of HIV exposure and acquisition. - A higher pre-test probability for a disease will **decrease the negative predictive value** of a test while increasing its positive predictive value, even if the test's sensitivity and specificity remain constant. *Decreased positive predictive value* - A higher **pre-test probability** (like in the 23-year-old patient) actually **increases the positive predictive value** of a diagnostic test, given the same sensitivity and specificity. - The positive predictive value reflects the probability that a positive test result correctly identifies someone with the disease. *Increased validity* - **Validity** refers to how well a test measures what it is supposed to measure (accuracy), and it is not expected to change based on the individual patient's risk factors. - The intrinsic properties of the test (sensitivity and specificity) determine its validity, not the prevalence of the disease or the patient's pre-test probability. *Increased sensitivity* - **Sensitivity** is a fixed characteristic of the test itself, defined as the proportion of true positives correctly identified by the test. - A patient's individual risk factors or pre-test probability do not alter the inherent sensitivity of the HIV test. *Increased specificity* - **Specificity** is also a fixed characteristic of the test, representing the proportion of true negatives correctly identified. - The test's specificity does not change based on the prevalence of HIV in the population or the patient's individual risk for the disease.

Question 17: An at-home recreational drug screening test kit is currently being developed. They consult you for assistance with determining an ideal cut-off point for the level of the serum marker in the test kit. This cut-off point will determine what level of serum marker is associated with a positive or negative test, with serum marker levels greater than the cut-off point indicative of a positive test and vice-versa. The cut-off level is initially set at 4 mg/uL, which is associated with a sensitivity of 92% and a specificity of 97%. How will the sensitivity and specificity of the test change if the cut-off level is raised to 6 mg/uL?

A. Sensitivity decreases, specificity decreases
B. Sensitivity decreases, specificity may increase or decrease
C. Sensitivity decreases, specificity increases (Correct Answer)
D. Sensitivity increases, specificity increases
E. Sensitivity increases, specificity decreases

Explanation: ***Sensitivity decreases, specificity increases*** - Raising the cut-off level means that the test will now require a **higher concentration of the serum marker** to be considered positive. This makes it harder for true positives to be identified (more false negatives), thus **decreasing sensitivity**. - Conversely, a higher cut-off makes it less likely for healthy individuals (true negatives) to mistakenly test positive (fewer false positives), leading to an **increase in specificity**. *Sensitivity decreases, specificity decreases* - This option is incorrect because **raising the cut-off point** typically has opposing effects on sensitivity and specificity, not a decrease in both. - A decrease in both would suggest a poorly designed or random change, which is not the expected outcome of systematically adjusting a threshold. *Sensitivity decreases, specificity may increase or decrease* - While it's true that real-world scenarios can be complex, for a single, direct change to a cut-off point, the relationship between sensitivity and specificity is generally inverse for a given test. - The uncertainty implied by "may increase or decrease" does not fully capture the predictable inverse relationship that occurs when adjusting a diagnostic threshold. *Sensitivity increases, specificity increases* - **Increasing sensitivity** and **increasing specificity** simultaneously is only achievable by improving the diagnostic test itself (e.g., using a better marker), not by simply adjusting a fixed cut-off point. - Adjusting a cut-off almost always involves a **trade-off** between these two metrics. *Sensitivity increases, specificity decreases* - This would occur if the cut-off level were **lowered**, not raised. - A lower cut-off would detect more true positives (increased sensitivity) but would also incorrectly classify more healthy individuals as positive (decreased specificity).

Question 18: A medical research study is beginning to evaluate the positive predictive value of a novel blood test for non-Hodgkin’s lymphoma. The diagnostic arm contains 700 patients with NHL, of which 400 tested positive for the novel blood test. In the control arm, 700 age-matched control patients are enrolled and 0 are found positive for the novel test. What is the PPV of this test?

A. 400 / (400 + 0) (Correct Answer)
B. 700 / (700 + 300)
C. 400 / (400 + 300)
D. 700 / (700 + 0)
E. 700 / (400 + 400)

Explanation: ***400 / (400 + 0) = 1.0 or 100%*** - The **positive predictive value (PPV)** is calculated as **True Positives / (True Positives + False Positives)**. - In this scenario, **True Positives (TP)** are the 400 patients with NHL who tested positive, and **False Positives (FP)** are 0, as no control patients tested positive. - This gives a PPV of 400/400 = **1.0 or 100%**, indicating that all patients who tested positive actually had the disease. *700 / (700 + 300)* - This calculation does not align with the formula for PPV based on the given data. - The denominator `(700+300)` suggests an incorrect combination of various patient groups. *400 / (400 + 300)* - The denominator `(400+300)` incorrectly includes 300, which is the number of **False Negatives** (patients with NHL who tested negative), not False Positives. - PPV focuses on the proportion of true positives among all positive tests, not all diseased individuals. *700 / (700 + 0)* - This calculation incorrectly uses the total number of patients with NHL (700) as the numerator, rather than the number of positive test results in that group. - The numerator should be the **True Positives** (400), not the total number of diseased individuals. *700 / (400 + 400)* - This calculation uses incorrect values for both the numerator and denominator, not corresponding to the PPV formula. - The numerator 700 represents the total number of patients with the disease, not those who tested positive, and the denominator incorrectly sums up values that don't represent the proper PPV calculation.

Question 19: A critical care fellow is interested in whether the auscultatory finding of pulmonary rales can accurately predict hypervolemic state. He conducts a study in 100 patients with volume overloaded state confirmed by a Swan Ganz catheter in his hospital's cardiac critical care unit. He also recruits 100 patients with euvolemic state confirmed by Swan Ganz catheter. He subsequently examines all patients in the unit for rales and finds that 80 patients in the hypervolemic group have rales in comparison to 50 patients in the euvolemic group. Which of the following is the positive predictive value of rales for the presence of hypervolemia?

A. 50/100
B. 80/100
C. 50/70
D. 80/130 (Correct Answer)
E. 100/200

Explanation: ***80/130*** - The **positive predictive value (PPV)** is the probability that a patient who tests positive for a disease (rales) actually has the disease (hypervolemia). It is calculated as **True Positives / (True Positives + False Positives)**. - In this study, 80 hypervolemic patients had rales (True Positives), and 50 euvolemic patients had rales (False Positives). Therefore, PPV = 80 / (80 + 50) = 80/130. *50/100* - This fraction represents the **false positive rate** for rales in this study (50 euvolemic patients with rales out of 100 euvolemic patients). - It does not account for the true positives or the overall positive test results, making it an incorrect calculation for PPV. *80/100* - This fraction represents the **sensitivity** of rales for hypervolemia (80 hypervolemic patients with rales out of 100 hypervolemic patients). - Sensitivity measures the proportion of actual positives that are correctly identified, not the positive predictive value. *50/70* - This fraction represents the **negative predictive value (NPV)**, which is the probability that a patient without rales (negative test) truly does not have hypervolemia. - NPV = True Negatives / (True Negatives + False Negatives) = 50 / (50 + 20) = 50/70, where 50 euvolemic patients lack rales and 20 hypervolemic patients lack rales. - While this is a valid epidemiological measure, the question specifically asks for PPV, not NPV. *100/200* - This represents the **overall prevalence of hypervolemia** in the entire study population (100 hypervolemic patients out of 200 total patients). - It does not consider the presence or absence of rales and is unrelated to the positive predictive value of rales.

Question 20: During an evaluation of a new diagnostic imaging modality for detecting salivary gland tumors, 90 patients tested positive out of the 100 patients who tested positive with the gold standard test. A total of 80 individuals tested negative with the new test out of the 100 individuals who tested negative with the gold standard test. What is the positive likelihood ratio for this test?

A. 80/90
B. 90/100
C. 90/20 (Correct Answer)
D. 90/110
E. 10/80

Explanation: ***90/20*** - The **positive likelihood ratio (LR+)** is calculated as **sensitivity / (1 - specificity)**. To calculate this, we first need to determine the values for true positives (TP), false positives (FP), true negatives (TN), and false negatives (FN). - Given that 90 out of 100 actual positive patients tested positive, **TP = 90** and **FN = 100 - 90 = 10**. Also, 80 out of 100 actual negative patients tested negative, so **TN = 80** and **FP = 100 - 80 = 20**. - **Sensitivity** is the true positive rate (TP / (TP + FN)) = 90 / (90 + 10) = 90 / 100. - **Specificity** is the true negative rate (TN / (TN + FP)) = 80 / (80 + 20) = 80 / 100. - Therefore, LR+ = (90/100) / (1 - 80/100) = (90/100) / (20/100) = **90/20**. *80/90* - This option incorrectly represents the components for the likelihood ratio. It seems to misinterpret the **true negative** count and the **true positive** count. - It does not follow the formula for LR+ which is **sensitivity / (1 - specificity)**. *90/100* - This value represents the **sensitivity** of the test, which is the proportion of true positives among all actual positives. - It does not incorporate the **false positive rate** (1 - specificity) in the denominator required for the positive likelihood ratio. *90/110* - This option incorrectly combines different values, possibly by confusing the denominator for sensitivity or specificity calculations. - It does not correspond to the formula for the **positive likelihood ratio**. *10/80* - This value seems to relate to the inverse of the **false negative rate** (10/100) or misrepresents the relationship between false negatives and true negatives. - It is not correctly structured to represent the **positive likelihood ratio (LR+)**.

Question 21: A 35-year-old man presents to his primary care provider in Philadelphia with a skin rash on his right thigh. He reports that the rash appeared 3 days ago. He recently returned from a weeklong trip to his vacation home in central Pennsylvania. He denies pain, numbness, paresthesias, itchiness, or burning around the rash. He does not recall finding any ticks on his body. He otherwise feels well. His past medical history is notable for gout. He takes allopurinol. He is an avid hiker and spends 3 months out of the year hiking. He does not smoke and drinks alcohol socially. On exam, he has a bullseye-like circular erythematous rash on the anterolateral aspect of his right thigh. The doctor decides to perform a new serum test for Lyme disease that was trialed at the same hospital in Philadelphia, where it was shown to have a sensitivity of 91% and specificity of 94%. The prevalence of Lyme disease in the area is among the highest in the country. How would the sensitivity and specificity of this new test change if it were performed on a patient in Texas, an area with a very low prevalence of Lyme disease?

A. Both sensitivity and specificity will decrease.
B. Sensitivity will decrease, and specificity will increase.
C. Both sensitivity and specificity will increase.
D. Sensitivity and specificity will remain the same. (Correct Answer)
E. Sensitivity will increase, and specificity will decrease.

Explanation: ***Sensitivity and specificity will remain the same.*** - **Sensitivity** and **specificity** are **intrinsic properties** of a diagnostic test that describe its ability to correctly identify diseased and non-diseased individuals, respectively, independent of **disease prevalence**. - While **predictive values (positive and negative predictive values)** are influenced by the **prevalence** of a disease in a given population, sensitivity and specificity are not. They reflect the test's performance characteristics regardless of how common the disease is in the population being tested. *Both sensitivity and specificity will decrease.* - This statement is incorrect because the **prevalence** of a disease does not alter the inherent ability of a test to correctly identify individuals with or without the disease; hence, sensitivity and specificity remain constant. - A change in prevalence would affect the **positive and negative predictive values**, not the test's fundamental sensitivity and specificity. *Sensitivity will decrease, and specificity will increase.* - This is incorrect because sensitivity and specificity are fixed characteristics of the test itself, determined during its validation. - The **prevalence** of the disease in a different population (e.g., Texas vs. Pennsylvania) does not change these intrinsic measures of test performance. *Both sensitivity and specificity will increase.* - This statement is incorrect as sensitivity and specificity are **independent** of **disease prevalence**. Better performance (higher sensitivity and specificity) would require a different, improved test, not merely testing in a different population. - The **inherent accuracy** of the test does not spontaneously improve or worsen based on where it is applied. *Sensitivity will increase, and specificity will decrease.* - This is incorrect because, as explained, **sensitivity** and **specificity** are inherent qualities of the test and are not influenced by the **prevalence** of the disease within a population. - Changes in prevalence affect the **likelihood of false positives and false negatives** when interpreting results, but not the test's fundamental ability to detect disease (sensitivity) or absence of disease (specificity).

Question 22: A research team is working on a new assay meant to increase the sensitivity of testing in cervical cancer. Current sensitivity is listed at 77%. If this research team's latest work culminates in the following results (listed in the table), has the sensitivity improved, and, if so, then by what percentage? Research team's latest results: | | Patients with cervical cancer | Patients without cervical cancer | |--------------------------|-------------------------------|----------------------------------| | Test is Positive (+) | 47 | 4 | | Test is Negative (-) | 9 | 44 |

A. No, the research team has seen a decrease in sensitivity according to the new results listed.
B. No, the research team has not seen any improvement in sensitivity according to the new results listed.
C. Yes, the research team has seen an improvement in sensitivity of almost 7% according to the new results listed. (Correct Answer)
D. Yes, the research team has seen an improvement in sensitivity of more than 10% according to the new results listed.
E. Yes, the research team has seen an improvement in sensitivity of less than 2% according to new results listed; this improvement is negligible and should be improved upon for significant contribution to the field.

Explanation: ***Yes, the research team has seen an improvement in sensitivity of almost 7% according to the new results listed.*** - **Sensitivity** is calculated as **True Positives / (True Positives + False Negatives)**. From the table: True Positives = 47, False Negatives = 9. - New sensitivity = 47 / (47 + 9) = 47 / 56 $\approx$ **83.9%**. Compared to the current sensitivity of 77%, this is an improvement of 83.9% - 77% = **6.9%**, which is almost 7%. *No, the research team has not seen any improvement in sensitivity according to the new results listed.* - The new sensitivity calculated is **83.9%**, which is indeed higher than the current sensitivity of **77%**. - This option incorrectly states there is no improvement, as a clear increase of nearly 7% is observed. *No, the research team has seen a decrease in sensitivity according to the new results listed.* - The calculated new sensitivity of **83.9%** is higher than the original 77%, indicating an **increase**, not a decrease. - This statement is factually incorrect based on the provided data. *Yes, the research team has seen an improvement in sensitivity of more than 10% according to the new results listed.* - The improvement is approximately **6.9%** (83.9% - 77%), which is less than 10%. - This option overstates the degree of improvement observed. *Yes, the research team has seen an improvement in sensitivity of less than 2% according to new results listed; this improvement is negligible and should be improved upon for significant contribution to the field.* - The calculated improvement is approximately **6.9%**, not less than 2%. - While clinical significance can be debated, the mathematical calculation of improvement is not accurately reflected by "less than 2%".

Question 23: A group of neurologists develop a new blood test for Alzheimer's. They are optimistic about the test, as they have found that for any given patient, the test repeatedly produces very similar results. However, they find that the new test results are not necessarily consistent with the gold standard of diagnosis. How would this new test most accurately be described?

A. Valid and reliable
B. Reliable (Correct Answer)
C. Valid
D. Biased
E. Neither valid nor reliable

Explanation: ***Reliable*** - The test produces **similar results repeatedly** upon repeated measures, indicating high **reliability** or **precision**. - Reliability refers to the **consistency** of a measure, even if it is not accurate. *Valid and reliable* - While the test is **reliable**, it is explicitly stated that the results are **not consistent with the gold standard**, meaning it lacks **validity**. - A test must be both **consistent** (reliable) and **accurate** (valid) to be described as valid and reliable. *Valid* - **Validity** refers to the **accuracy** of a test, or how well it measures what it is supposed to measure. - The test is explicitly stated to **not be consistent with the gold standard**, indicating a lack of agreement with the true measure of Alzheimer's. *Biased* - **Bias** refers to a **systematic error** in measurement that can lead to consistently high or low results compared to the true value. - While the test might be biased due to its lack of consistency with the gold standard, "biased" is not the most accurate single descriptor of its measurement properties given the information provided. *Neither valid nor reliable* - The test is described as producing **very similar results repeatedly**, which directly indicates it has **high reliability**. - Therefore, stating it is neither valid nor reliable is incorrect, as it possesses reliability.

Question 24: You conduct a medical research study to determine the screening efficacy of a novel serum marker for colon cancer. The study is divided into 2 subsets. In the first, there are 500 patients with colon cancer, of which 450 are found positive for the novel serum marker. In the second arm, there are 500 patients who do not have colon cancer, and only 10 are found positive for the novel serum marker. What is the overall sensitivity of this novel test?

A. 450 / (450 + 10)
B. 490 / (10 + 490)
C. 490 / (50 + 490)
D. 450 / (450 + 50) (Correct Answer)
E. 490 / (450 + 490)

Explanation: ***450 / (450 + 50)*** - **Sensitivity** is defined as the proportion of actual positive cases that are correctly identified by the test. - In this study, there are **500 patients with colon cancer** (actual positives), and **450 of them tested positive** for the marker, while **50 tested negative** (500 - 450 = 50). Therefore, sensitivity = 450 / (450 + 50) = 450/500 = 0.9 or 90%. *450 / (450 + 10)* - This formula represents **Positive Predictive Value (PPV)**, which is the probability that a person with a positive test result actually has the disease. - It incorrectly uses the total number of **test positives** in the denominator (450 true positives + 10 false positives) instead of the total number of diseased individuals, which is needed for sensitivity. *490 / (10 + 490)* - This is actually the correct formula for **specificity**, not sensitivity. - Specificity = TN / (FP + TN) = 490 / (10 + 490) = 490/500 = 0.98 or 98%, which measures the proportion of actual negative cases correctly identified. - The question asks for sensitivity, not specificity. *490 / (50 + 490)* - This formula incorrectly mixes **true negatives (490)** with **false negatives (50)** in an attempt to calculate specificity. - The correct specificity formula should use false positives (10), not false negatives (50), in the denominator: 490 / (10 + 490). *490 / (450 + 490)* - This calculation incorrectly combines **true negatives (490)** and **true positives (450)** in the denominator, which does not correspond to any standard epidemiological measure. - Neither sensitivity nor specificity uses both true positives and true negatives in the denominator.

Question 25: You are developing a new diagnostic test to identify patients with disease X. Of 100 patients tested with the gold standard test, 10% tested positive. Of those that tested positive, the experimental test was positive for 90% of those patients. The specificity of the experimental test is 20%. What is the positive predictive value of this new test?

A. 10%
B. 90%
C. 95%
D. 11% (Correct Answer)
E. 20%

Explanation: ***11%*** - The positive predictive value (PPV) is calculated as **true positives / (true positives + false positives)**. - From 100 patients, 10 have disease (prevalence 10%). With 90% sensitivity, the test correctly identifies **9 true positives** (90% of 10). - Of 90 patients without disease, specificity of 20% means 20% are correctly identified as negative (18 true negatives), so **72 false positives** = 90 × (1 - 0.20). - Therefore, PPV = 9 / (9 + 72) = 9/81 = **11.1% ≈ 11%**. *10%* - This value represents the **prevalence** of the disease in the population, not the positive predictive value of the test. - Prevalence is the proportion of individuals who have the disease (10 out of 100 patients). *90%* - This figure represents the **sensitivity** of the test, which is the percentage of true positives correctly identified by the experimental test. - Sensitivity = true positives / (true positives + false negatives) = 9/10 = 90%. *95%* - This value is not directly derivable from the given data and does not represent any standard test characteristic in this context. - It would imply a much higher PPV than what can be calculated given the low specificity of 20%. *20%* - This is the stated **specificity** of the test, which measures the proportion of true negatives correctly identified. - Specificity = true negatives / (true negatives + false positives) = 18/90 = 20%.

Question 26: A medicine resident on her nephrology rotation notices that she has received more alerts of high serum potassium levels on her patients through the hospital electronic medical record despite her census not having changed. On inspection of the laboratory result reports, critical alert markers are seen for potassium values greater than 5.5 mEq/L 3 days ago, whereas the same alerts are seen for values > 5.0 mEq/L since yesterday. One of her patient's nurses asks if the patient should get an electrocardiogram. How has the potassium value reporting been affected?

A. Sensitivity increased and specificity increased
B. Sensitivity decreased and specificity increased
C. Sensitivity increased and specificity unchanged
D. Sensitivity decreased and specificity decreased
E. Sensitivity increased and specificity decreased (Correct Answer)

Explanation: ***Sensitivity increased and specificity decreased*** - Lowering the alert threshold from **>5.5 mEq/L** to **>5.0 mEq/L** means more true positives (patients with actual hyperkalemia) will be identified, thus **increasing sensitivity**. - However, this also means more false positives (patients without clinically significant hyperkalemia triggering an alert) will occur, thereby **decreasing specificity**. *Sensitivity increased and specificity increased* - This option would imply that the test is better at identifying both true positives and true negatives, which is not the case when only the threshold is changed. - While sensitivity increases by lowering the threshold, specificity invariably decreases, as more benign cases are flagged. *Sensitivity decreased and specificity increased* - This scenario would occur if the threshold were raised (e.g., from >5.0 mEq/L to >5.5 mEq/L), which would miss more true cases but reduce false alarms. - The alert range change described (from >5.5 to >5.0) directly opposes this outcome. *Sensitivity decreased and specificity decreased* - This would indicate a significant worsening of the test's ability to correctly identify both cases and non-cases, which is not directly supported by merely adjusting a threshold. - While specificity does decrease, sensitivity increases, making this option incorrect. *Sensitivity increased and specificity unchanged* - Changing the threshold will impact both sensitivity and specificity, making it impossible for specificity to remain unchanged if sensitivity increases. - A threshold adjustment always involves a trade-off between sensitivity and specificity; improving one typically impacts the other.

Question 27: A rapid diagnostic test has been developed amid a major avian influenza outbreak in Asia. The outbreak has reached epidemic levels with a very high attack rate. Epidemiologists are hoping to use the rapid diagnostic test to identify all exposed individuals and curb the rapid spread of disease by isolating patients with any evidence of exposure to the virus. The epidemiologists compared rapid diagnostic test results to seropositivity of viral antigen via PCR in 200 patients. The findings are represented in the following table: Test result PCR-confirmed avian influenza No avian influenza Positive rapid diagnostic test 95 2 Negative rapid diagnostic test 5 98 Which of the following characteristics of the rapid diagnostic test would be most useful for curbing the spread of the virus via containment?

A. Positive predictive value of 95/97
B. Specificity of 98/100
C. Sensitivity of 95/100 (Correct Answer)
D. Negative predictive value of 98/103
E. Accuracy of 193/200

Explanation: ***Sensitivity of 95/100*** - In an epidemic with a **high attack rate** and the goal of **identifying all exposed individuals** to prevent spread, a test with **high sensitivity** is crucial. - **Sensitivity** measures the proportion of true positives that are correctly identified (95/100 = 95%), meaning it correctly identifies those *with* the disease, thus minimizing **false negatives** and ensuring all infected individuals are isolated. - When the primary objective is containment and preventing disease spread, missing even a few infected individuals (false negatives) could perpetuate the epidemic. *Positive predictive value of 95/97* - **Positive predictive value (PPV)** indicates the probability that a positive test result truly reflects the presence of the disease (95/97 = 97.9%). - While important for confirming disease in individuals, it's less critical than sensitivity for the primary goal of **identifying all exposed individuals** in an epidemic to prevent further spread. *Specificity of 98/100* - **Specificity** measures the proportion of true negatives that are correctly identified (98/100 = 98%), meaning it correctly identifies those *without* the disease. - In this scenario, while important to avoid unnecessary isolation, high specificity is secondary to high sensitivity when the main objective is to **curb rapid disease spread by finding all infected individuals**. *Negative predictive value of 98/103* - **Negative predictive value (NPV)** indicates the probability that a negative test result truly reflects the absence of the disease (98/103 = 95.1%). - While valuable for ruling out disease, high NPV is not the most critical characteristic when the primary goal is to **identify all infected individuals** to contain an epidemic. *Accuracy of 193/200* - **Accuracy** represents the overall proportion of correct results, both positive and negative (193/200 = 96.5%). - While accuracy provides an overall measure of test performance, it doesn't specifically address the critical need to **minimize false negatives** in a containment scenario where missing infected individuals is the primary concern.

Question 28: A group of investigators is evaluating the diagnostic properties of a new blood test that uses two serum biomarkers, dityrosine and Nε-carboxymethyl-lysine, for the clinical diagnosis of autism spectrum disorder (ASD) in children. The test is considered positive only if both markers are found in the serum. 50 children who have been diagnosed with ASD based on established clinical criteria and 50 children without the disorder undergo testing. The results show: Diagnosis of ASD No diagnosis of ASD Test positive 45 15 Test negative 5 35 Which of the following is the specificity of this new test?

A. 10%
B. 88%
C. 70% (Correct Answer)
D. 90%
E. 30%

Explanation: ***70%*** - **Specificity** measures the proportion of **true negatives** among all actual negatives. It is calculated as True Negatives / (True Negatives + False Positives). - In this study, there are 35 true negatives (children without ASD who tested negative) and 15 false positives (children without ASD who tested positive). Therefore, Specificity = 35 / (35 + 15) = 35 / 50 = **0.70 or 70%**. *10%* - This value is not directly interpretable as a standard diagnostic property from the given data. - It might represent a calculation error or a misinterpretation of a different metric. *88%* - This value does not correspond to any standard diagnostic test property calculated from the given 2x2 table. - It might result from a calculation error or confusion between different metrics (e.g., an incorrect attempt at calculating positive predictive value or sensitivity). - The actual **positive predictive value** would be 45 / (45 + 15) = 45/60 = **75%**, not 88%. *90%* - This value represents the **sensitivity** of the test, calculated as True Positives / (True Positives + False Negatives) = 45 / (45 + 5) = 45/50 = 0.90 or 90%. - Sensitivity measures the ability of the test to correctly identify those with the disease, not those without it. *30%* - This value represents the proportion of **false positives** among all actual negatives (False Positives / (True Negatives + False Positives) = 15 / (35 + 15) = 15/50 = 0.30 or 30%). - This is **1 - specificity**, not specificity itself.

Question 29: A new real time-PCR test for the hepatitis C virus is approved for medical use. The manufacturer sets the threshold number of DNA copies required to achieve a positive result such that the sensitivity is 98% and the specificity is 80%. The tested population has a hepatitis C prevalence of 0.7%. Which of the following changes in the prevalence, incidence, or threshold concentration will increase the positive predictive value of the test, if the other two values are held constant?

A. A decrease in incidence
B. A decrease in prevalence
C. An increase in prevalence (Correct Answer)
D. Lowering the threshold concentration required for a positive test.
E. An increase in incidence

Explanation: ***An increase in prevalence*** - An increase in **prevalence** directly leads to an increase in the **positive predictive value (PPV)** as it means there are more true positives in the tested population relative to false positives. - PPV is calculated as (True Positives) / (True Positives + False Positives), and a higher prevalence increases the likelihood that a positive test result genuinely indicates the presence of the disease. *A decrease in incidence* - **Incidence** refers to the rate of new cases, while **prevalence** is the total proportion of individuals with the disease at a given time. - The PPV formula depends directly on **prevalence**, not incidence. Since the question specifies that other values are held constant, a change in incidence alone (with prevalence held constant) would have *no direct effect* on PPV. *A decrease in prevalence* - A **decrease in prevalence** would lead to a lower likelihood of a positive test result being a true positive, thus *decreasing* the **positive predictive value (PPV)**. - With fewer true cases in the population, a higher proportion of positive results would be false positives, negatively impacting the PPV. *Lowering the threshold concentration required for a positive test* - **Lowering the threshold concentration** for a positive test would increase the test's **sensitivity** (detecting more true positives) but *decrease* its **specificity** (leading to more false positives). - A decrease in specificity, especially in a low-prevalence setting (0.7%), would significantly increase the number of false positives, thereby *decreasing* the **positive predictive value (PPV)**. *An increase in incidence* - **Incidence** measures the rate of new cases over time, while the PPV formula depends directly on **prevalence** (the proportion with disease at a given time). - Since the question specifies that other values are held constant, an increase in incidence with prevalence held constant would have *no direct effect* on PPV. Incidence only affects PPV indirectly through its eventual impact on prevalence, but this pathway is blocked by the constraint.

Question 30: A 36-year-old female presents to clinic inquiring about the meaning of a previous negative test result from a new HIV screening test. The efficacy of this new screening test for HIV has been assessed by comparison against existing gold standard detection of HIV RNA via PCR. The study includes 1000 patients, with 850 HIV-negative patients (by PCR) receiving a negative test result, 30 HIV-negative patients receiving a positive test result, 100 HIV positive patients receiving a positive test result, and 20 HIV positive patients receiving a negative test result. Which of the following is most likely to increase the negative predictive value for this test?

A. Decreased prevalence of HIV in the tested population (Correct Answer)
B. Increased prevalence of HIV in the tested population
C. Increased number of false positive test results
D. Increased number of false negative test results
E. Decreased number of false positive test results

Explanation: ***Decreased prevalence of HIV in the tested population*** - A **lower prevalence** of a disease in the population means there are fewer actual cases, making a **negative test result** more reliable in ruling out the disease. - This increases the probability that a person with a negative test truly does not have the disease, thus elevating the **negative predictive value (NPV)**. *Increased prevalence of HIV in the tested population* - A **higher prevalence** means there are more actual cases of HIV in the population. - In this scenario, a negative test result is less reassuring, as there's a greater chance of missing a true positive case, leading to a **decreased NPV**. *Increased number of false positive test results* - **False positives** are instances where a test indicates disease when it's not present; they do not directly impact the ability of a negative test to predict absence of disease. - While they affect the **positive predictive value (PPV)**, they do not directly alter the reliability of a negative result to exclude disease, so the NPV is not increased. *Increased number of false negative test results* - **False negatives** occur when a test indicates no disease, but the disease is actually present. - An increase in false negatives directly implies that a negative test result is less trustworthy, leading to a **decrease in the NPV**. *Decreased number of false positive test results* - A decrease in false positive results primarily improves the **positive predictive value (PPV)**. - While it indicates a more accurate test overall, it does not directly affect NPV, which measures the reliability of a negative test result in ruling out disease.

Question 31: A novel PET radiotracer is being evaluated for its ability to aid in the diagnosis of Alzheimer’s disease (AD). The study decides to use a sample size of 1,000 patients, and half of the patients enrolled have AD. In the group of patients with AD, 400 are found positive on the novel type of PET imaging examination. In the control group, 50 are found positive. What is the PPV of this novel exam?

A. 400 / (400+50) (Correct Answer)
B. 450 / (450 + 100)
C. 400 / (400+100)
D. 450 / (450 + 50)
E. 400 / (400 + 150)

Explanation: ***400 / (400+50)*** - The **Positive Predictive Value (PPV)** is the probability that subjects with a positive test result actually have the disease. It's calculated as **True Positives / (True Positives + False Positives)**. - In this scenario, **True Positives** are 400 (patients with AD who tested positive), and **False Positives** are 50 (control patients without AD who tested positive). *450 / (450 + 100)* - This calculation incorrectly includes **False Negatives** (450, total AD patients - true positives) in the numerator or denominator for PPV, and misidentifies other components. - The formula for PPV specifically focuses on positive test results and the proportion of those that are truly disease-positive. *400 / (400+100)* - This option correctly identifies **True Positives** as 400 but incorrectly assumes **False Positives** are 100. - The problem states that 50 control patients (without AD) tested positive, which are the false positives. *450 / (450 + 50)* - This formula incorrectly uses **450** as the number of **True Positives**, which represents the total number of patients with AD testing positive and negative (400 TP + 100 FN). - PPV only considers those who tested positive in its numerator. *400 / (400 + 150)* - While 400 is correctly identified as **True Positives**, the **False Positives** are incorrectly stated as 150. - The problem explicitly states that 50 control patients were found positive, making 50 the correct number for false positives.

Question 32: A new assay for Lyme disease has been developed. While the assay has been tested extensively in Maine, a group of inventors are planning to test it in Southern California. In comparison to the assay's performance in Maine, testing the assay in Southern California would affect the performance of the assay in which of the following ways?

A. Greater likelihood that an individual with a positive test will truly have Lyme disease
B. Decreased positive likelihood ratio of the Lyme disease assay
C. Decrease negative likelihood ratio of the Lyme disease assay
D. Lower likelihood that a patient without Lyme disease truly has a negative test
E. Greater likelihood that an individual with a negative test will truly not have Lyme disease (Correct Answer)

Explanation: ***Greater likelihood that an individual with a negative test will truly not have Lyme disease*** - This scenario describes an increase in the **negative predictive value (NPV)** of the assay. In an area with lower disease prevalence (Southern California compared to Maine for Lyme disease), the NPV increases because there are fewer true cases to miss, making a negative result more reliable in ruling out the disease. - The intrinsic properties of the test (sensitivity and specificity) remain the same, but the interpretation of its results is influenced by the **pre-test probability** (prevalence). *Greater likelihood that an individual with a positive test will truly have Lyme disease* - This describes an increase in the **positive predictive value (PPV)**. This would occur if the test were moved to an area with higher **prevalence**, not lower prevalence like Southern California for Lyme disease. - In an area with lower prevalence, the PPV would actually **decrease**, meaning a positive test is less likely to represent a true positive. *Decreased positive likelihood ratio of the Lyme disease assay* - The **likelihood ratio (LR)** of a diagnostic test is an intrinsic property that depends on its **sensitivity** and **specificity**, and it is generally independent of disease prevalence. - Therefore, moving the test to an area with different prevalence should not change its positive likelihood ratio. *Decrease negative likelihood ratio of the Lyme disease assay* - Similar to the positive LR, the **negative likelihood ratio** is an intrinsic characteristic of the test (calculated from sensitivity and specificity). - It remains constant regardless of the **disease prevalence** in the population being tested. *Lower likelihood that a patient without Lyme disease truly has a negative test* - This statement describes a decrease in **specificity** (a decrease in the true negative rate) or an increase in the **false negative rate**. - The intrinsic **specificity** of the assay does not change with population prevalence, only the interpretation of the results through metrics like predictive values.

Question 33: A genetic population study is being conducted to find the penetrance of a certain disease. This disease is associated with impaired iron metabolism and primarily affects the liver. Patients often present with diabetes and bronze skin pigmentation. After a genetic screening of 120 inhabitants with a family history of this disease, 40 were found to have the disease-producing genotype, but only 10 presented with symptoms. What are the chances of the screened patients with said genotype developing the disease phenotype?

A. 0.4%
B. 40%
C. 3%
D. 4%
E. 25% (Correct Answer)

Explanation: ***25%*** - **Penetrance** is calculated as the proportion of individuals with a specific genotype who express the associated phenotype. - In this case, 10 individuals out of 40 with the disease-producing genotype developed symptoms, so (10 / 40) * 100% = **25%**. *0.4%* - This value is significantly lower than the actual penetrance and likely results from an incorrect calculation or misinterpretation of the given data. - It does not accurately reflect the proportion of genotypically affected individuals who express the phenotype. *40%* - This percentage represents the proportion of screened individuals with the disease-producing genotype (40 out of 120 are ~33%), not the penetrance itself. - It incorrectly equates the presence of the genotype in the population with the expression of the phenotype. *3%* - This value is likely obtained by an erroneous calculation, possibly by dividing the symptomatic individuals by the total screened population (10/120 ≈ 8.3%), which does not represent penetrance. - It does not account for the specific individuals who possess the genotype. *4%* - This percentage might arise from an incorrect division or a misunderstanding of what constitutes penetrance. - It is an inaccurate representation of the ratio between phenotype expression and genotype presence.

Question 34: A geriatric investigator is evaluating the consistency of Alzheimer dementia diagnoses based on clinical symptoms. Patients with known chart diagnoses of Alzheimer dementia were evaluated by multiple physicians during a fixed time interval. Each evaluator was blinded to the others' assessments. The extent to which the diagnosis by one physician was replicated by another clinician examining the same patient is best described by which of the following terms?

A. Validity
B. Specificity
C. Predictive value
D. Sensitivity
E. Precision (Correct Answer)

Explanation: ***Precision*** - **Precision** refers to the consistency or reproducibility of a measurement or diagnosis. When multiple physicians reach the same diagnosis for the same patient, it indicates high precision. - In this context, it specifically assesses **inter-rater reliability**, which is the extent to which different observers agree on the same assessment. *Validity* - **Validity** refers to the extent to which a test or measure accurately assesses what it is intended to measure. It is about the "truthfulness" of the diagnosis. - While important for diagnosis, validity is about accuracy against a gold standard, not consistency among different observers. *Specificity* - **Specificity** is the ability of a test to correctly identify individuals who do *not* have the disease (true negatives). - It measures the proportion of healthy individuals who are correctly identified as healthy by the test, which is not what is being evaluated here. *Predictive value* - **Predictive value** assesses the probability that a person *actually has* (positive predictive value) or *does not have* (negative predictive value) a disease given their test result. - This concept relates to the diagnostic utility of a test in a population, not the consistency of different clinician diagnoses. *Sensitivity* - **Sensitivity** is the ability of a test to correctly identify individuals who *do* have the disease (true positives). - It measures the proportion of diseased individuals who are correctly identified as diseased by the test, which is distinct from inter-rater agreement.

Question 35: An infectious disease investigator is evaluating the diagnostic accuracy of a new interferon-gamma-based assay for diagnosing tuberculosis in patients who have previously received a Bacillus Calmette-Guérin (BCG) vaccine. Consenting participants with a history of BCG vaccination received an interferon-gamma assay and were subsequently evaluated for tuberculosis by sputum culture. Results of the study are summarized in the table below. Tuberculosis, confirmed by culture No tuberculosis Total Positive interferon-gamma assay 90 6 96 Negative interferon-gamma assay 10 194 204 Total 100 200 300 Based on these results, what is the sensitivity of the interferon-gamma-based assay for the diagnosis of tuberculosis in this study?

A. 90/96
B. 100/300
C. 194/200
D. 90/100 (Correct Answer)
E. 194/204

Explanation: ***90/100*** - **Sensitivity** measures the proportion of **true positive** cases that are correctly identified by the test. - In this study, there are 90 true positive results (positive interferon-gamma assay in patients with confirmed tuberculosis) out of a total of 100 individuals with confirmed tuberculosis (90 + 10). *90/96* - This calculation represents the **positive predictive value** (90 true positives / 96 total positive tests). - It answers the question: "If the test is positive, what is the likelihood that the patient actually has the disease?" *100/300* - This value represents the prevalence of tuberculosis in the study population (100 confirmed cases / 300 total participants). - It does not reflect a measure of the test's diagnostic accuracy. *194/200* - This value represents the **specificity** of the test (194 true negatives / 200 total individuals without tuberculosis). - Specificity measures the proportion of true negative cases that are correctly identified by the test. *194/204* - This calculation represents the **negative predictive value** (194 true negatives / 204 total negative tests). - It answers the question: "If the test is negative, what is the likelihood that the patient does not have the disease?"

Question 36: You are reviewing raw data from a research study performed at your medical center examining the effectiveness of a novel AIDS screening examination. The study enrolled 250 patients with confirmed AIDS, and 240 of these patients demonstrated a positive screening examination. The control arm of the study enrolled 250 patients who do not have AIDS, and only 5 of these patients tested positive on the novel screening examination. What is the NPV of this novel test?

A. 240 / (240 + 15)
B. 240 / (240 + 5)
C. 240 / (240 + 10)
D. 245 / (245 + 10) (Correct Answer)
E. 245 / (245 + 5)

Explanation: ***245 / (245 + 10)*** - The **negative predictive value (NPV)** is calculated as **true negatives (TN)** divided by the sum of **true negatives (TN)** and **false negatives (FN)**. - In this study, there are 250 patients with AIDS; 240 tested positive (true positives, TP), meaning 10 tested negative (false negatives, FN = 250 - 240). There are 250 patients without AIDS; 5 tested positive (false positives, FP), meaning 245 tested negative (true negatives, TN = 250 - 5). Therefore, NPV = 245 / (245 + 10). *240 / (240 + 15)* - This calculation incorrectly uses the number of **true positives** (240) in the numerator and denominator, which is relevant for **positive predictive value (PPV)**, not NPV. - The denominator `(240 + 15)` does not correspond to a valid sum for calculating NPV from the given data. *240 / (240 + 5)* - This calculation incorrectly uses **true positives** (240) in the numerator, which is not part of the NPV formula. - The denominator `(240 + 5)` mixes true positives and false positives, which is incorrect for NPV. *240 / (240 + 10)* - This incorrectly places **true positives** (240) in the numerator instead of **true negatives**. - The denominator `(240+10)` represents **true positives + false negatives**, which is related to sensitivity, not NPV. *245 / (245 + 5)* - This calculation correctly identifies **true negatives** (245) in the numerator but incorrectly uses **false positives** (5) in the denominator instead of **false negatives**. - The denominator for NPV should be **true negatives + false negatives**, which is 245 + 10.

Question 37: A new screening test utilizing a telemedicine approach to diagnosing diabetic retinopathy has been implemented in a diabetes clinic. An ophthalmologist’s exam was also performed on all patients as the gold standard for diagnosis. In a pilot study of 500 patients, the screening test detected the presence of diabetic retinopathy in 250 patients. Ophthalmologist exam confirmed a diagnosis of diabetic retinopathy in 200 patients who tested positive in the screening test, as well as 10 patients who tested negative in the screening test. What is the sensitivity, specificity, positive predictive value, and negative predictive value of the screening test?

A. Sensitivity = 83%, Specificity = 95%, PPV = 96%, NPV = 80%
B. Sensitivity = 95%, Specificity = 83%, PPV = 80%, NPV = 96% (Correct Answer)
C. Sensitivity = 83%, Specificity = 95%, PPV = 80%, NPV = 96%
D. Sensitivity = 95%, Specificity = 83%, PPV = 96%, NPV = 80%
E. Sensitivity = 80%, Specificity = 95%, PPV = 96%, NPV = 83%

Explanation: ***Sensitivity = 95%, Specificity = 83%, PPV = 80%, NPV = 96%*** - From the data (Total patients = 500): - **True Positives (TP)** = 200 (Screening test positive, ophthalmologist confirmed) - **False Negatives (FN)** = 10 (Screening test negative, but ophthalmologist confirmed) - **Total Diseased** = TP + FN = 200 + 10 = 210 - **Total Non-Diseased** = Total patients - Total Diseased = 500 - 210 = 290 - **False Positives (FP)** = (Patients positive on screening) - TP = 250 - 200 = 50 - **True Negatives (TN)** = Total Non-Diseased - FP = 290 - 50 = 240 - Calculations: - **Sensitivity** = TP / (TP + FN) = 200 / (200 + 10) = 200 / 210 ≈ **95.2%** - **Specificity** = TN / (TN + FP) = 240 / (240 + 50) = 240 / 290 ≈ **82.8%** - **Positive Predictive Value (PPV)** = TP / (TP + FP) = 200 / (200 + 50) = 200 / 250 = **80%** - **Negative Predictive Value (NPV)** = TN / (TN + FN) = 240 / (240 + 10) = 240 / 250 = **96%** *Sensitivity = 83%, Specificity = 95%, PPV = 96%, NPV = 80%* - This option incorrectly reverses the **sensitivity** and **specificity** values. - The calculated **PPV** and **NPV** are also incorrect for this option. *Sensitivity = 83%, Specificity = 95%, PPV = 80%, NPV = 96%* - This option incorrectly states the **sensitivity** and **specificity** values by swapping their true calculations. - While **PPV** and **NPV** match our calculated values, the first two metrics are flawed. *Sensitivity = 95%, Specificity = 83%, PPV = 96%, NPV = 80%* - This option correctly identifies **sensitivity** and **specificity**, but incorrectly provides **PPV** and **NPV**. - The **PPV** and **NPV** values are effectively swapped or miscalculated compared to the true values. *Sensitivity = 80%, Specificity = 95%, PPV = 96%, NPV = 83%* - This option incorrectly states all four calculated values: **sensitivity**, **specificity**, **PPV**, and **NPV**. - It demonstrates a misunderstanding of how to correctly apply the formulas for each of these metrics.

Practice by Chapter

Definitions and calculations

Practice Questions

2x2 contingency tables

Practice Questions

Relationship with false positive/negative rates

Practice Questions

Positive predictive value (PPV)

Practice Questions

Negative predictive value (NPV)

Practice Questions

Effect of disease prevalence on predictive values

Practice Questions

Likelihood ratios

Practice Questions

ROC curve analysis

Practice Questions

Area under the curve (AUC) interpretation

Practice Questions

Optimizing cut-off values

Practice Questions

Trade-offs between sensitivity and specificity

Practice Questions

Multi-test algorithms

Practice Questions

Application to screening programs

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free